



#### Report from the Steering Group: Reflections

Presented by: Ingemar Persson, ENCePP Steering Group

London, 23 November 2011









Name	Affiliation		
Corinne de Vries	University of Bath, United Kingdom		
Joan-Ramon Laporte	Fundació Institut Català de Farmacologia, Barcelona / Spain		
Ingemar Persson (Vice Chair)	Centre for Pharmacoepidemiology (CPE) at the Department of Medicine,		
	Karolinska Institutet, Stockholm / Sweden		
Miriam Sturkenboom	Erasmus MC, Rotterdam / Netherlands		
Giuseppe Traversa	Istituto Superiore di Sanità, Rome / Italy		
Hans-Georg Eichler	European Medicines Agency		
Peter Arlett (Chair)	European Medicines Agency		
Henry Fitt	European Medicines Agency		
Stella Blackburn	European Medicines Agency		
Jytte Lyngvig	Lægemiddelstyrelsen - Danish Medicines Agency, Denmark		
Hubert Leufkens	College ter Beoordeling van Geneesmiddelen, Netherlands		
June Munro Raine	Medicines and Healthcare Products Regulatory Agency, UK		
David Haerry	European AIDS Treatment Group, Brussels, Belgium		
Yola Moride	Faculty of Pharmacy, Université de Montréal, Canada		
Nicholas Moore	Université Victor Segalen, Departement de Pharmacologie (INSERM), France		
Valerie Simmons	Lilly UK		
Xavier Kurz	EMA – Principal Advisor		
Jim Slattery	EMA – Statistical Advisor		






# Chronology

11 Dec 2009	SG Elec	SG Election & start of 2-year mandate		
2010	• No. of n	No. of meetings: 7 (2 face-to-face)		
	• 1 <sup>st</sup> DIA	ENCePP Info Day		
2011	• No. of n	neetings: 6 (2 face-to-face)		
	• 1 <sup>st</sup> Jouri	nal Editors Workshop		
	• 2 <sup>nd</sup> DIA	ENCePP Info Day		
23 Nov 2011	• End of r	nandate		













#### **Classification of centres**







#### Experience with study designs



Increase in capacity across study design





# Work Plans: shift in focus



- Adoption ENCePP Work Plans 2010 and 2011-2012 and publication on ENCePP website
- 2010: to have in place by the end of the year a high-quality, *self-sustainable network* in the field of independent post-authorisation monitoring of medicinal products in the EU
- 2011-2012: Building on the initial phase of establishment, the priority is to *consolidate ENCePP* as an important and internationally renowned resource in the field of pharmacovigilance and pharmacoepidemiology that delivers for health protection and promotion.





# Key Milestones in terms of the network itself

- Establishment of ENCePP Steering Group (SG) in January 2010.
- Launch of ENCePP Database of Research Resources (centres and networks) on 31 January 2010 (<u>http://www.encepp.eu/encepp/resourcesDatabase.jsp</u>)
- Launch of Database of data sources in April 2010 (<u>http://www.encepp.eu/encepp/resourcesDatabase.jsp</u>)
- Launch of Members Forum on ENCePP Website in April 2010 (<u>http://www.encepp.eu/jforum/forums/list.page</u>)





# Major outputs: Standards

•Adoption of *Checklist* of Methodological Standards for ENCePP Study Protocols March 2010

- Adoption of Revision1: ENCePP Checklist for Study Protocols Jun 2010 (renamed to reflect broader update outside ENCePP studies e.g. also in risk management planning, regulatory agencies assessment of protocols)
- Adoption of ENCePP *Guide* on Methodological Standards in Pharmacoepidemiology (following public consultation) May 2011





### Major outputs: Independence

- Adoption of ENCePP *Code* of Conduct (May 2010)
  - Adoption of Revisions 1 (September 2010) and 2 of Code (October 2011)
- Development and launch of ENCePP study concept, including the "ENCePP seal" June 2010 (development of a communication package consisting of leaflet, press release, publication on EMA public website)
- Adoption by the SG of 'access to data' policy and implementing rules in relation to ENCePP study data (September 2010) – now included in Revision 2





## Major outputs: Transparency

 Creation of a fully functional *database of post-authorisation studies*. The ENCePP e-register of studies was launched to the public during the ENCePP Plenary meeting on 18 November 2010 (<u>http://www.encepp.eu/encepp/studiesDatabase.jsp</u>).

• Liaison with EUNetHA and EnprEMA initiated to potentially broaden the scope of the network to further cover *health outcome research and paediatric research*.

• Exploration of the merits of developing an *accreditation system* and its features has started.





## Increasing visibility of the network

- Workshop with Medical Journals Editors June 2011 on the aims of ENCePP as regards independency and transparency in research and to increase the visibility of the network to the broader scientific community.
- Reassurance given that posting results will not impact negatively in terms of subsequent publication
- Pharmacoepidemiology and Drug Safety (Nov 2011): *author guidelines* modified
- to encourage authors to release results of public health importance
- to recommend posting protocols in the ENCePP register





### Promotion of ENCePP

- Promotion of ENCePP at a number of *international conferences* and symposia.
- Organisation of the two "*ENCePP Information days*" in collaboration with DIA November 2010 and November 2011 targeted at pharmaceutical industry staff.
- Continued contact with international initiatives with complementary objectives including *FDA and Health Canada* activities to exchange information and consider complementarity





## Interaction with Third parties

• Adoption of ENCePP Linking Policy re. placing announcements on the *ENCePP website* October 2011

 Guidance on Third Party announcements finalised November 2011: allows for industry to post announcements including, for example, requests for collaboration in the conduct of studies in the ENCePP Partners Forum


- Presented to DIA at 2<sup>nd</sup> Infoday and to PhVWP Nov 2011
- Well received
- For further announcement/dissemination





#### Other achievements

- ENCePP response to public consultation on *personal data protection in the EU* (SG sponsors: M. Sturkenboom & C. de Vries)
  - Follow-up visit to DG Justice
- ENCePP response to the public consultation on revision of the *Clinical Trials Directive*
- Adoption of strategy for *impact evaluation* of ENCePP
- ENCePP partners *survey*







#### **ENCePP Studies**

#### 4 Studies found

Status	Official Title	Lead Investigator	Last Updated
Ongoing	International Active Surveillance study - Folate and Oral Contraceptive Utilization Study	Dr Juergen Dinger	03/01/2011
Planned	Impact of risk minimisation in patients treated with rosiglitazone- containing products	Professor Henrik Toft Sørensen	15/02/2011
Planned	International Active Surveillance Study of Women Taking Dienogest for Endometriosis: Visanne Post-approval Observational Study	Dr Juergen Dinger	03/01/2011
Planned	Cong-term outcomes and adverse events of therapy with inhaled corticosteroids, long-acting beta-2-agonists and anticholinergic drugs in hospitalised patients with Chronic Obstructive Pulmonary Disease (COPD) - a cohort study based on health information systems in three Italian regions.	Dr Nera Agabiti	27/10/2010

Small numbers but early days yet and a lot has been learned





## Essential ongoing deliverables

- Development of approaches to facilitate the conduct of multinational studies in light of existing differences in *data privacy laws across the EU*, in collaboration with Working Group 3.
- Further defining the role of ENCePP as regards its *interaction with regulatory decision-making* and in light of the changes introduced by the new Pharmacovigilance legislation.
- Ensuring that the *ENCePP Studies database* feeds in, as appropriate, to any international discussions on standardisation of data fields, including WHO platform and ISO.





#### Personal reflection

We, especially regulators, came from *the need* to create better resources for Pharmacovigilance and Risk Management in the EU.

Now we have a network *system in place* with competence centres, data resources and rules for conduct – offered to all stakeholders to the best of collaboration and interactions.

The ENCePP system has the *potential* to meet challenges of modern pharmacovigilance and requirements of the new legislation.

It is time for ENCePP to be increasingly *recognized and used*. Its *promotion and faclitatation* will be important tasks over the next years.

